The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper.

Photodynamic diagnosis (PDD) significantly enhances the detection of bladder cancer (BCa) and is able to reduce the risk of disease recurrence, although it may not affect disease progression and mortality rates. Despite its advantages, widespread adoption of PDD is limited by cost considerations and the absence of unified guidelines on its application, highlighting the need for continued evaluation of its cost-effectiveness across different healthcare settings. To date, no specific recommendations for PDD in non-muscle invasive bladder cancer (NMIBC) management have been provided by the Italian Society of Urology (Società Italiana di Urologia, SIU).

Contemporary rates and predictors of prolonged hospital stay after radical cystectomy: a population-based analysis.

Objective: To test contemporary rates and predictors of prolonged hospital stay after radical cystectomy (RC) and ileal conduit in non-metastatic bladder cancer patients.

Methods: Within the National Inpatient Sample database (NIS, 2008-2019), we identified ileal conduit RC patients and tabulated length of stay (LOS) ≥ 75th percentile vs. others.

Robot-assisted vs. open radical cystectomy: octogenarians vs. non octogenarians.

Introduction: We quantified the effect of robot-assisted radical cystectomy (RARC) vs. open radical cystectomy (ORC) on adverse in-hospital outcomes in octogenarians (≥80 years) relative to non-octogenarians.

Material And Methods: Propensity score matching (PSM), multivariable logistic and Poisson regression models focused on adverse in-hospital outcomes in octogenarian and non-octogenarian patients treated with RARC vs.

The Effect of Valvulopathy on Adverse In-Hospital Outcomes After Partial and Radical Nephrectomy.

Background: The effect of valvulopathy on adverse in-hospital outcomes after partial nephrectomy (PN) and radical nephrectomy (RN) is unknown.

Patients And Methods: Descriptive analyses, 1:2 propensity score matching and multivariable logistic and Poisson regression models were used to address National Inpatient Sample (2000-2019) patients with kidney cancer who underwent PN and RN, stratified according to presence or absence of valvulopathy.

Results: Overall, 38,673 patients underwent PN versus 92,072 RN.

Extracorporeal vs. intracorporeal urinary diversion at robot-assisted radical cystectomy: adverse in-hospital outcomes.

The advantage of intracorporeal (ICUD) over extracorporeal urinary diversion (ECUD) at robot-assisted radical cystectomy (RARC) regarding adverse in-hospital outcomes is still under debate. We addressed these knowledge gap in the National Inpatient Sample (2016-2019). RARC patients receiving either ileal conduit or neobladder were stratified according to UD technique (ECUD vs.

Robot-assisted kidney transplantation using right- vs. left-sided grafts from living donors: a prospective multicenter study from the ERUS-RAKT working group.

Background: Kidney transplantation using right-sided graft (RSG) is technically challenging and may be associated with increased risk of complications and/or suboptimal graft function. Our study aims to compare perioperative and functional outcomes of robot-assisted kidney transplantation (RAKT) using RSG vs. left-sided graft (LSG).

Early Outcomes from the Multicentre Standardised PHysician Modified Four Fenestration Endograft REgistry (S.PH.E.RE.).

Objective: The objective of the study was to investigate the safety, efficacy, and early outcomes of a novel standardised approach to a four fenestration physician modified endograft (sPMEG) in the treatment of very large and urgent complex abdominal aortic aneurysms (cAAAs).

Methods: This was a prospective multicentre study (S.PH.

Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in T2N0M0 Urothelial Bladder Cancer.

Background: The authors hypothesized that for T2N0M0 urothelial carcinoma of urinary bladder (UCUB) patients, partial cystectomy (PC) does not differ from radical cystectomy (RC) regarding cancer-specific mortality (CSM).

Methods: Within the Surveillance, Epidemiology and End Results (SEER) database (2004-2021), rates of PC versus RC for T2N0M0 UCUB patients were tabulated. Nearest-neighbor 1:1 propensity score-matching (PSM) for age, sex, tumor size and site, race/ethnicity, chemotherapy, and pelvic lymph node dissection status was applied.

Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study.

Unlabelled: IXE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) in randomized controlled trials (RCTs). However, available data on long-term persistence of therapy are scarce.

Methods: This multi-center study aimed to evaluate the drug retention rate (DRR) of IXE in a real-world setting and to identify key factors influencing treatment persistence.

Costs of robot-assisted vs. open approaches for 5 major cancers.

To test for differences in total hospital cost (THC) between robot-assisted vs. open major cancer surgeries, colectomy, esophagectomy, radical hysterectomy, lung resection and pancreatectomy. Within the National Inpatient Sample (2016-2019), we identified all robot-assisted vs.

Oncological outcomes after non-surgical management versus radical cystectomy in non-organ-confined non-urothelial bladder cancer.

Introduction: We hypothesized that among non-organ-confined (NOC, T3-4 and/or N1-3) non-urothelial carcinoma of urinary bladder (non-UCUB) patients, bladder-sparing non-surgical management (NSM) provides cancer-specific mortality (CSM) rates comparable to those of radical cystectomy (RC).

Methods: Within the SEER database (2004-2021) rates of NSM vs. RC use in NOC non-UCUB patients were tabulated.

Effect of chemotherapy on cancer specific mortality in female locally advanced urethral cancer.

Objective: To quantify the effect of chemotherapy (CHT) in locally advanced female primary urethral cancer (fPUC).

Methods: In the Surveillance, Epidemiology and Ends Results (SEER) database (2000-2021), we identified 295 fPUC patients with locally advanced stage treated with local therapy (surgery or radiation or both) with or without CHT. Multivariable Cox regression models addressed cancer specific mortality free survival (CSM).

Salvage treatment of local recurrence following radical and partial nephrectomy.

Purpose Of Review: Standardized definition of local recurrence after radical or partial nephrectomy is still lacking. Due to its rarity, data on natural history, oncological outcomes and prognostic factors are scarce and specific treatment recommendations cannot be made.

Recent Findings: Surgery is still the preferred option to treat a local recurrence of renal cell carcinoma, with favorable survival outcomes.

Hospital Volume as a Determinant of Outcomes After Partial Nephrectomy: A Systematic Review by the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

The influence of surgical volume on partial nephrectomy (PN) outcomes is a subject of debate. The European Association of Urology (EAU) renal cell carcinoma (RCC) guideline panel performed a protocol-driven systematic review of the association between hospital volume (HV) and oncological, functional, and complication outcomes following PN for RCC. The intervention was PN performed in a higher-volume hospital (defined according to the number of procedures per unit time) and the comparator was PN performed in a lower-volume hospital.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update.

Background And Objective: The European Association of Urology (EAU) renal cell carcinoma (RCC) guideline panel has updated their evidence-based guidelines and recommendations for the management of RCC. Here we present a summary of the 2025 RCC guidelines updated with standardised methodology to provide reproducible evidence for the management of RCC.

Methods: For the 2025 update, a literature search was performed covering the period from May 1, 2023 to May 1, 2024 using the Medline, EMBASE, and Cochrane Libraries.

The effect of chronic kidney disease on adverse in-hospital outcomes after radical cystectomy with ileal conduit urinary diversion.

Purpose: Chronic kidney disease (CKD) is frequent in bladder cancer patients undergoing radical cystectomy (RC) with ileal conduit. However, the effect of CKD on adverse in-hospital outcomes after ileal conduit RC is not well known.

Methods: Descriptive analyses, propensity score matching (PSM), and multivariable logistic and Poisson regression models were used to address National Inpatient Sample patients treated with ileal conduit RC between 2006 and 2019.

Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.

The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse. The TiNivo and CONTACT-03 trials have reported results for subsequent therapy after progression on ICI therapy in the metastatic setting. The European Association of Urology (EAU) RCC guidelines panel reassessed the new trial results to update recommendations for adjuvant therapy and post-adjuvant therapy.

Baseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study.

Background: Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important to choose the most effective treatment according to patients' characteristics. Apremilast is recommended in PsA with moderate activity.

Robot-assisted Kidney Transplantation: The 8-year European Experience.

Background And Objective: Evidence regarding perioperative results and long-term functional outcomes of robotic-assisted kidney transplantation (RAKT) is limited. We evaluated perioperative surgical results and long-term functional outcomes of RAKT in patients receiving kidney transplants from living donors.

Methods: This retrospective analysis is based on a prospective multicenter cohort study conducted from July 2015 to October 2023 across ten European centers.

Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter Study.

The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related to cardiovascular and cancer risks, prompted a need for additional investigation in real-world clinical settings. This study aimed to evaluate the long-term effectiveness and predictors of response to TOFA in two subpopulations of RA patients, categorized by differing cardiovascular risk profiles.

Reply to Wei Qi's letter to the editor about "Preoperative proteinuria correlates with renal function after partial nephrectomy for renal cell carcinoma".

In this Letter, we respond to Wei Qi's Letter to the editor regarding our paper, "Preoperative proteinuria correlates with renal function after partial nephrectomy for renal cell carcinoma" (World Journal of Urology, 2024), addressing the concerns raised with the aim of clarifying the potential benefits of our findings in clinical practice.

Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis.

Background: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the efficacy of UPA to obtain remission or low disease activity (LDA) in a series of UPA patients in patients with RA after 6 and 12 months of treatment in a real-world setting.